Study shows new breast cancer drug letrozole shrinks tumors more effectively than tamoxifen

December 10, 2001

SAN ANTONIO, Texas - A new cancer drug called letrozole (trade name Femara®) worked better at shrinking breast cancer tumors than did the front-line breast cancer drug tamoxifen among a group of postmenopausal women with estrogen-positive tumors, according to a study coordinated by a Duke University Medical Center physician.

Sixty percent of women taking letrozole showed tumor shrinkage after four months on the drug, whereas 41 percent of women taking tamoxifen showed tumor shrinkage. Patients taking letrozole also underwent fewer mastectomies (complete breast removal) than women who were taking tamoxifen. Moreover, letrozole actually slowed the rate of cell division -- and hence, tumor growth - better than tamoxifen did, according to cellular studies conducted on the actual tumors.

Results of the study are being presented Monday, Dec. 10, at the 24th Annual San Antonio Breast Cancer Symposium. The study was funded by Novartis Pharmaceuticals Corp., which manufactures letrozole. "We are very excited by letrozole's potential because it appears to block the growth-promoting effects of estrogen within cancer cells better than tamoxifen does," said Dr. Mathew Ellis, a Duke oncologist and lead author of the study. "Estrogen is involved in up to 80 percent of all breast cancers, so blocking its effects is vital to successful treatment.

"Although our results are preliminary, letrozole appears to block estrogen more effectively than does tamoxifen, suggesting that letrozole may work for women whose tumors are relatively resistant to tamoxifen," Ellis said. Letrozole could even replace the more toxic chemotherapy drugs in some patients, or it could be taken together with other non-cytotoxic drugs like Herceptin for maximum effect, the researchers theorize. Its distinct mechanism of action makes letrozole quite different from current therapies like tamoxifen and other, more toxic chemotherapies, Ellis said.

Ellis cautioned that, while his results are highly significant, they must be replicated in larger and more standard types of studies. The current study design was unique because it examined the drugs' ability to shrink tumors before women had surgery to remove their tumors rather than after surgery, as is commonly done to eradicate any undetected cancer cells. Also, the sample size of 324 women is not large enough upon which to base a change in routine clinical practice, he said.

Letrozole works by depriving the tumor of estrogen. Specifically, letrozole inhibits an enzyme called aromatase, which converts the male hormone androgen into the female hormone estrogen. Women taking letrozole, therefore, make almost no estrogen at all. Without estrogen, tumor cells that rely on the hormone for growth cannot divide and do not continue to grow.

Tamoxifen has a very different mechanism of action. It binds to small sites in the cancer cell called estrogen "receptors" and blocks estrogen from docking there. The receptors, plugged up with tamoxifen instead of estrogen, initiate a different sequence of events than they would in the presence of estrogen.

However, tamoxifen's presence on the receptor still triggers some estrogen-regulated genes to exert their influence within the cell, albeit in ways not fully understood. This effect may blunt the effectiveness of tamoxifen against some breast cancers.

Ellis says letrozole's ability to completely block estrogen from the cell is, in part, responsible for its apparent benefits over tamoxifen in some women. In addition, he said, tamoxifen allows two other proteins - called ErbB-1 and ErbB-2 -- to amplify the growth-promoting effects of estrogen inside the cell. Letrozole, on the other hand, nullifies the action of these proteins because they rely on the estrogen receptor being stimulated to exert their action.

Knowing how the ErbB-1 and ErbB-2 proteins interact with the estrogen receptor to promote cancer is vital for several reasons, Ellis said. If researchers can identify which women express these proteins in their cancer cells, they can use them as biological "markers" to predict which women will respond to a given cancer treatment.

For example, women whose tumors made or "expressed" either of these proteins (ErbB-1 or ErbB-2) appeared to be largely resistant to the effects of tamoxifen, the study showed. Letrozole, however, was very effective in these types of tumors, shrinking them in 88 percent of women.

Several upcoming studies will compare letrozole's effects to tamoxifen in larger numbers of breast cancer patients, said Ellis. These larger studies should provide abundant data to confirm or refute letrozole's effects.
-end-
Ellis is a consultant for Novartis Pharmaceuticals Corp. and a member of their speakers' bureau. Joining Ellis in the study were researchers from Universitaets Frauen-und Poliklinik, Hamburg, Germany; Instituto Valenciano de Oncologia, Valencia, Spain; Institut Bergonie, Bordeaux, France; and West General Hospital, Edinburgh, United Kingdom.

Note to editors: A color image of Dr. Matthew Ellis is available at http://dukemednews.duke.edu/gallery/detail.php?id=304

Contact: Richard Puff or Amy Austell at 919-684-4148, or via email at richard.puff@duke.edu or amy.austell@duke.edu

Duke University Medical Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.